Literature DB >> 10388987

Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.

T J Berg1, O Snorgaard, J Faber, P A Torjesen, P Hildebrandt, J Mehlsen, K F Hanssen.   

Abstract

OBJECTIVE: Impairment of left ventricular diastolic function, possibly caused by increased collagen cross-linking of the cardiac muscle, is common in patients with type 1 diabetes even without coronary artery disease. Advanced glycation end products (AGEs) cross-link tissue collagen and are found within myocardial fibers. The aim of this study was to examine for a possible association between circulating AGEs and left ventricular cardiac function. RESEARCH DESIGN AND METHODS: Left ventricular diastolic and systolic function were assessed by M-mode and Doppler echocardiography in 52 patients with type 1 diabetes, age 40 +/- 13 (mean +/- SD) years, diabetes duration 17 +/- 13 years, and HbA1c 8.3 +/- 1.1%. Serum levels of AGEs and N epsilon-(carboxymethyl)lysine (CML) were measured by newly developed competitive immunoassays.
RESULTS: A positive correlation was found between serum levels of AGEs and isovolumetric relaxation time (IVRT), r = 0.46 (P < 0.0008), and left ventricular diameter during diastole, r = 0.37 (P < 0.008). The systolic parameters did not correlate with serum levels of AGEs. Stepwise regression analysis showed that 21% of the IVRT variation could be explained by serum levels of AGEs (F = 11.4, P < 0.002), whereas serum levels of CML, HbA1c, albumin excretion rate, diabetes duration, and mean arterial blood pressure were of no importance. AGE levels were significantly increased in men compared with women (P < 0.03) and present or former smokers (P < 0.04).
CONCLUSIONS: Increased serum levels of AGEs, unlike serum levels of CML, are associated with heart stiffness in patients with type 1 diabetes, possibly mediated by the cross-linking properties of AGEs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10388987     DOI: 10.2337/diacare.22.7.1186

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  45 in total

Review 1.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

2.  Clinical efficacy of 'Spleen-kidney-care' Yiqi Huayu and Jiangzhuo traditional Chinese medicine for the treatment of patients with diabetic nephropathy.

Authors:  Hong Liu; Jin Zheng; Rong-Heng Li
Journal:  Exp Ther Med       Date:  2015-07-07       Impact factor: 2.447

3.  Prevention of diabetes-induced myocardial dysfunction in rats using the juice of the Emblica officinalis fruit.

Authors:  Snehal S Patel; Ramesh K Goyal
Journal:  Exp Clin Cardiol       Date:  2011

Review 4.  Diabetic cardiomyopathy: do women differ from men?

Authors:  Jun Ren; Asli F Ceylan-Isik
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

5.  Advanced glycation end products in myocardial reperfusion injury.

Authors:  Peter Celec; Július Hodosy; Peter Jáni; Pavol Janega; Matúš Kúdela; Marta Kalousová; Johana Holzerová; Vojtech Parrák; Lukáč Halčák; Tomáš Zima; Martin Braun; Ivan Pecháň; Ján Murín; Katarína Šebeková
Journal:  Heart Vessels       Date:  2011-05-12       Impact factor: 2.037

Review 6.  Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.

Authors:  Kailash Prasad; Indu Dhar; Gudrun Caspar-Bell
Journal:  Int J Angiol       Date:  2015-06

7.  Advanced glycation end products promote proliferation of cardiac fibroblasts by upregulation of KCa3.1 channels.

Authors:  Li-Mei Zhao; Wei Zhang; Li-Ping Wang; Gui-Rong Li; Xiu-Ling Deng
Journal:  Pflugers Arch       Date:  2012-10-02       Impact factor: 3.657

8.  Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?

Authors:  Josephine M Forbes; Georgia Soldatos; Merlin C Thomas
Journal:  Clin Biochem Rev       Date:  2005-11

Review 9.  Nonischemic heart failure in diabetes mellitus.

Authors:  Ashrith Guha; Romain Harmancey; Heinrich Taegtmeyer
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

Review 10.  Pre-clinical diastolic dysfunction.

Authors:  Siu-Hin Wan; Mark W Vogel; Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.